A landmark clinical trial has demonstrated that VERVE-102, a novel gene-editing therapy, can reduce LDL cholesterol by up to 84% with a single intravenous injection. The phase 1 study, published in The New England Journal of Medicine, represents the first successful human application of in vivo base editing technology for cardiovascular disease treatment.
The therapy works by permanently modifying the PCSK9 gene in liver cells, effectively disabling production of a protein that prevents cholesterol removal from the bloodstream. Unlike traditional statins, which require daily medication adherence, this approach could potentially provide lifelong cholesterol reduction from one treatment.
Ten patients with severe familial hypercholesterolemia and established cardiovascular disease participated in the trial. The procedure was well-tolerated, with no serious adverse events reported during the 180-day follow-up period, though some participants experienced mild, transient infusion-related symptoms.
Read the full article on GMJ Newsroom.
Was this article helpful?
